SEC Form 4 · accession 0000899243-17-027813
Clovis Oncology, Inc. · CLVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel W Muehl
Officer — See Remarks
Period of report
Nov 29, 2017
Accepted (ET)
Dec 1, 2017 · 4:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001466301
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 29, 2017 | M | 547 | — | A | 2,875 | D | |
| Common Stock | Nov 29, 2017 | F | 259 | $59.49 | D | 2,616 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF2,F1 | — | Nov 29, 2017 | M | 547 | D | — | — | Common Stock | 547 | 6,015 | D |
Explanation of responses
- F1Each Restricted Stock Unit represents the right to receive one share of Common Stock.
- F2On August 25, 2016, the reporting person was granted 8,750 Restricted Stock Units. 25% of such Restricted Stock Units vested on August 25, 2017, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
Remarks
Senior Vice President of Finance, Principal Financial Officer and Principal Accounting Officer